Search

Search Constraints

You searched for: Author/Creator Valcárcel, David

Search Results

1. A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome. Issue 9 (23rd June 2014)

2. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. (12th December 2018)

3. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. (December 2017)

4. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Issue 6 (12th May 2019)

5. Ex vivo T‐cell depletion vs post‐transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft‐vs‐host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. (18th October 2020)

6. Excess mortality in the myelodysplastic syndromes. Issue 2 (7th December 2016)

7. Frequency, characteristics, and outcome of PTLD after allo‐SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). (10th April 2019)

8. Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. Issue 10 (3rd October 2015)

9. Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies. (5th July 2020)

10. Multivariate time‐dependent comparison of the impact of lenalidomide in lower‐risk myelodysplastic syndromes with chromosome 5q deletion. (10th April 2014)